And that’s a wrap 2023! Christmas with IR Department

2023 has been another exciting year for the team. In this blog post, the IR Department team provides their reflections on one interesting fact or lesson they learnt this year, and one favourite book/podcast (or TV series) recommendation.

December 8th, 2023 by Phillipa Thorn
Read More

IR Department expands with ESG practice and new team members

  • New ESG practice bolsters consultancy’s client offering
  • Appointment of Jack McLintock, Annabelle Dick and Anna Cvijetić expand IR Department’s investor and public relations expertise
July 4th, 2023 by IR Department
Read More

IWD2023 interview series, Feature Five: Gertrude Biomedical CEO/Managing Director, Tara Karnezis

Tara Karnezis is the Chief Executive Officer and Managing Director of IR Department’s client, Gertrude Biomedical. Tara oversees Gertrude’s development of small molecule medicines that target cancer growth and spread.

We were grateful to her for giving us some time as part of our International Women's Day interview series, to discuss her perspective on this year’s theme, “Embracing Equity”.

March 27th, 2023 by Phillipa Thorn
Read More

IWD2023 interview series, Feature Four: HaemaLogiX Chair/CEO, Bryce Carmine

Bryce Carmine is the Chairman and Chief Executive Officer with IR Department’s client, HaemaLogiX, a private Australian biotech company developing immune-based treatments for multiple myeloma.

We were grateful for Bryce giving us some time, as part of our International Women's Day series, to share some insights and perspective on this year’s theme, “Embracing Equity”.

March 23rd, 2023 by Phillipa Thorn
Read More

IWD2023 interview series, Feature Three: Pureprofile’s COO/CFO, Melinda Sheppard

Melinda Sheppard is the Chief Operating Officer and Chief Financial Officer with IR Department client, Pureprofile Limited (ASX: PPL). Together with CEO Martin Filz, Melinda has been instrumental in the turnaround of the Pureprofile business over the past few years.

We were grateful that she could spend some time with us as part of our International Women's Day series, to share some insights from her career and her perspective on this year’s theme, “Embracing Equity”.

March 20th, 2023 by Phillipa Thorn
Read More

IWD2023 – Mary Harney talks about the importance of mentoring and optimism

As part of International Women’s Day 2023, IR Department sat down with leaders across a range of industries to discuss their unique perspectives on the theme of “embracing equity”.

In this interview, we speak with Mary Harney (pictured), who is Non-Executive Director for our client, Race Oncology (ASX: RAC), and also Chair of both Oncology One and Microbio.

Mary has had a fascinating career history across health and agricultural sectors. A thoughtful, analytical and persuasive leader, Mary’s positive influence has seen prominent businesses and cultures transformed. A constant throughout her career has been the wealth of opportunity created for both women and men through mentoring and career championship.

March 17th, 2023 by Jane Lowe
Read More

IWD2023 interview series, Feature One: Servatus' Non-Executive Director Eilis Quinn

Eilis Quinn is General Manager, Australia and New Zealand at Jazz Pharmaceuticals and is also Non-Executive Director with IR Department client, Servatus. 

Recently Eilis took some time out to chat with our Communications Director, Cherie Hartley about International Women’s Day, her experiences and perspectives around this year’s theme, “Embracing Equity”.

March 13th, 2023 by Phillipa Thorn
Read More

Getting started with ESG – what’s it all about?

ESG (environmental, social, and governance) has become a key factor for investors when making investment decisions. As such, incorporating ESG into your investor relations approach is crucial for success.

Our latest blog post explores the benefits of ESG for companies, including attracting socially responsible investors, managing risks, building a positive brand reputation, and ensuring regulatory compliance. We also provide practical tips on how to integrate ESG into your investor relations approach. Read our blog post now and learn how to build a sustainable and responsible business that benefits all stakeholders. 

February 18th, 2023 by Jane Lowe
Read More

Podcast - IR Department talks to Race Oncology's CSO Dr Daniel Tillett

Our Digital Content Producer, Paul Langley, talks with Race Oncology's CSO Dr Daniel Tillett, who explains how the recent clinical trials are evolving and what it means for the future. He gives a brief overview on the history of Race, their aspirations and milestones for development and eventual commercialisation of Zantrene.

August 29th, 2022 by Paul Langley
Read More

Podcast - IR Department talks with AdAlta CEO & MD, Dr Tim Oldham

Our Communications Director, Cherie Hartley, talks with AdAlta's CEO & M.D. Dr Tim Oldham at this year's Bioshares Biotech Summit, who takes us inside the mind of a biotech company. He discussed the importance of focus for a platform company, explains why making decisions on a day-to-day basis is so crucial for risk reduction and why they're investing in supporting core strategies as well as their target product profile.

July 4th, 2022 by Cherie Hartley
Read More

IRD Invest March 2022 - Openpay

IRD Invest March 2022 - "Project: 2025"

Watch the replay of Openpay's CEO (Australia & New Zealand) Dion Appel.

March 31st, 2022 by Paul Langley
Read More

IRD Invest March 2022 - Oventus

IRD Invest 31st March 2022 - "Project: 2025"

Watch the replay of Oventus CEO John Cox's presentation.

March 31st, 2022 by Paul Langley
Read More

IRD Invest March 2022 - Pureprofile

IRD Invest 31st March 2022 - "Project: 2025"

Watch the replay of Pureprofile CEO Martin Filz's presentation.

March 31st, 2022 by Paul Langley
Read More

Interview with Ben Fogarty, CEO (UK) XPON

We speak to Ben Fogarty, CEO (UK & Europe) from XPON Technologies Group (see video below) about what the future holds for them and the impact of the upcoming ‘Metaverse’.

March 17th, 2022 by Paul Langley
Read More

A groundbreaking approach to cancer treatment

A number of breakthrough discoveries for Race Oncology's (ASX:RAC) drug Zantrene® over the past 18 months has seen the company evolve its strategy and clinical programs in order to maximise these opportunities. What does the future for Race look like?

March 16th, 2022 by Paul Langley
Read More